BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21319215)

  • 1. The role of TLE1 in synovial sarcoma.
    Seo SW; Lee H; Lee HI; Kim HS
    J Orthop Res; 2011 Jul; 29(7):1131-6. PubMed ID: 21319215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.
    Knösel T; Heretsch S; Altendorf-Hofmann A; Richter P; Katenkamp K; Katenkamp D; Berndt A; Petersen I
    Eur J Cancer; 2010 Apr; 46(6):1170-6. PubMed ID: 20189377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.
    Peng C; Guo W; Yang Y; Zhao H
    Eur J Cancer Prev; 2008 Oct; 17(5):392-8. PubMed ID: 18714179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma.
    Jagdis A; Rubin BP; Tubbs RR; Pacheco M; Nielsen TO
    Am J Surg Pathol; 2009 Dec; 33(12):1743-51. PubMed ID: 19809272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies.
    Terry J; Saito T; Subramanian S; Ruttan C; Antonescu CR; Goldblum JR; Downs-Kelly E; Corless CL; Rubin BP; van de Rijn M; Ladanyi M; Nielsen TO
    Am J Surg Pathol; 2007 Feb; 31(2):240-6. PubMed ID: 17255769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics.
    Foo WC; Cruise MW; Wick MR; Hornick JL
    Am J Clin Pathol; 2011 Jun; 135(6):839-44. PubMed ID: 21571956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma.
    Valente AL; Tull J; Zhang S
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):408-13. PubMed ID: 23197007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
    Horiuchi K; Morioka H; Nishimoto K; Suzuki Y; Susa M; Nakayama R; Kawai A; Sonobe H; Takaishi H; Ozaki T; Yabe H; Umezawa K; Toyama Y
    Cancer Lett; 2008 Dec; 272(2):336-44. PubMed ID: 18760530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin induces cell senescence preferentially over apoptosis in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Bastar JD; Randall RL
    J Orthop Res; 2006 Jun; 24(6):1163-9. PubMed ID: 16705698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins.
    Kawauchi S; Fukuda T; Oda Y; Saito T; Oga A; Takeshita M; Yokoyama K; Chuman H; Iwamoto Y; Sasaki K; Tsuneyoshi M
    Mod Pathol; 2000 Jul; 13(7):755-65. PubMed ID: 10912935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms.
    Kosemehmetoglu K; Vrana JA; Folpe AL
    Mod Pathol; 2009 Jul; 22(7):872-8. PubMed ID: 19363472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue microarray based immunohistochemical study of TLE1 in synovial sarcoma and its histologic mimics.
    Sivakoti S; Uppin SG; Uppin MS; Tara RP; Prayaga AK; Challa S
    Indian J Pathol Microbiol; 2021; 64(2):310-315. PubMed ID: 33851625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas.
    Rekhi B; Basak R; Desai SB; Jambhekar NA
    Indian J Med Res; 2012 Nov; 136(5):766-75. PubMed ID: 23287123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.
    Fraga MF; Berdasco M; Ballestar E; Ropero S; Lopez-Nieva P; Lopez-Serra L; Martín-Subero JI; Calasanz MJ; Lopez de Silanes I; Setien F; Casado S; Fernandez AF; Siebert R; Stifani S; Esteller M
    Cancer Res; 2008 Jun; 68(11):4116-22. PubMed ID: 18519670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation.
    Watanabe T; Tsuda M; Tanaka S; Ohba Y; Kawaguchi H; Majima T; Sawa H; Minami A
    Mol Cancer Res; 2009 Sep; 7(9):1582-92. PubMed ID: 19737974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transducer-like Enhancer of Split 1 as a Novel Immuno- histochemical Marker for Diagnosis of Synovial Sarcoma.
    Atef A; Alrashidy M
    Asian Pac J Cancer Prev; 2015; 16(15):6545-8. PubMed ID: 26434872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low expression of p27(Kip1), a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma.
    Kawauchi S; Goto Y; Liu XP; Furuya T; Oga A; Oda Y; Tsuneyoshi M; Ihara K; Sasaki K
    Cancer; 2001 Mar; 91(5):1005-12. PubMed ID: 11251953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.